Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Teriflunomide (Aubagio)

Notes:
^ Adequate trial is defined as at least 3-month treatment duration
* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary teriflunomide (Aubagio) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a Neurologist
- Diagnosis of Relapsing form of Multiple Sclerosis (MS), including:
  - Non-Progressive Relapsing MS
  - Progressive Relapsing MS
  - Relapsing Remitting MS
- Patient has failed an adequate trial^ of or patient has an allergy or intolerance* to glatiramer acetate AND interferon beta-1a (Avonex, Rebif) or interferon beta-1b (Extavia, Betaseron)
- Patient is not a candidate for rituximab per prescribing neurologist
- Female patient is not pregnant or planning pregnancy; male patient is not planning pregnancy with partner

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary teriflunomide (Aubagio) will be covered on the prescription drug benefit when the following criteria are met:

- See below for Continued use criteria for patients stable on the medication

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously. Non-formulary teriflunomide (Aubagio) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Diagnosis of Multiple Sclerosis
- Currently stable on medication
Teriflunomide (Aubagio)

Continued use criteria for patients stable on the medication: Non-formulary teriflunomide (Aubagio) will continue to be covered on the prescription drug benefit for 24 months when the following criteria are met:

- Prescribed by a Neurologist
- Low/no new/active brain MRI lesions (no more than 1 in 1 year; no more than 2 in 2 years, etc.)
- Female patient is not pregnant or planning pregnancy; male patient is not planning pregnancy with partner
- Patient has completed the following laboratory monitoring within the last 12 months:
  - Liver function test (alanine aminotransferase, ALT)
  - Complete blood count with differential (CBC w/ diff)
- Patient is NOT using teriflunomide with another disease modifying treatment including: dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b, natalizumab, ocrelizumab, or rituximab